Labs/Biomarkers

What’s New in Psoriatic Arthritis: A Whirlwind Tour At #EULAR2026, Prof. Dennis McGonagle highlighted three key PsA trends: the rise of single-cell and spatial transcriptomics, progress toward personalized care (though not yet fully realized), and the next frontier of defining https://t.co/zN4K92UnW9
Dr. John Cush @RheumNow( View Tweet )
RA-ILD: Screening risk and genetic susceptibility Two abstracts presented at EULAR 2026 add important insights into identifying patients at risk for RA-ILD and understanding the genetic mechanisms that may underpin disease development. https://t.co/IABp8NhUtS https://t.co/j8UHK2GRd7

Links:

Dr. John Cush @RheumNow( View Tweet )
Renal Biopsies in SLE Dr. Andrea Fava reporting from EULAR 2026 in London. https://t.co/naCyEAutbb https://t.co/XgdiXY3hiO

Links:

Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

EULAR 2026 Rheumatology RoundUp

Jack Cush, MD

It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.

Read Article
Obinutuzumab drives histologic remission in lupus nephritis At #EULAR2026, new data from the phase III REGENCY trial add to the case for obinutuzumab in lupus nephritis. Investigators report deep intrarenal B-cell depletion and significantly higher rates of histological https://t.co/AlJ5I8s2JE
Dr. John Cush @RheumNow( View Tweet )
EULAR meeting room

NK Cells Without a CAR: AB-101 Is Neither CAR-T nor CAR-NK

Henrique Dalmolin, MD

Much of the meeting came for the next CAR T readout. AB-101 drew attention for a different reason. It depletes B cells by a completely different route.

Read Article
What’s New in Psoriatic Arthritis: A Whirlwind Tour At #EULAR2026, Prof. Dennis McGonagle highlighted three key PsA trends: the rise of single-cell and spatial transcriptomics, progress toward personalized care (though not yet fully realized), and the next frontier of defining https://t.co/IzsSzx6Pc9
Dr. John Cush @RheumNow( View Tweet )
MRI as a novel biomarker in lupus The clinical abstract sessions at #EULAR2026 on diagnostic tools in lupus showcased interesting studies, including the use of MRI, as potential non-invasive biomarkers. https://t.co/TK2gqSxAg5 https://t.co/5Qj8KXWgub

Links:

Dr. John Cush @RheumNow( View Tweet )
This study evaluated the risk of flares after sustained drug-free rem in SLE. % of pts w/ reported flares w/n yrs in rem: 48.6% at 2yrs 42.3% at 3yrs 35.2% at 5 yrs Mucocut, msk, renal & immuno - ⬆️affected domain Reassess pts regularly. POS1354 @RheumNow #EULAR2026 https://t.co/DG0yNOW1nh

Links:

sheila @RHEUMarampa( View Tweet )
EULAR.Docs.APP

Day 4 EULAR Report

Jack Cush, MD

The last day in London was exciting as both the Late-Breaking abstracts and new EULAR guidelines were presented. Guidelines presented addressed several significant unmet need areas including PMR, GCA, Takayasu’s arteritis, Vaccinations in Rheumatic patients, Imaging in spondyloarthritis and

Read Article
lupus.nephritis.immunofluorescence.jpg

Obinutuzumab drives histologic remission in lupus nephritis

Mrinalini Dey, MD

At EULAR 2026, investigators are presenting perhaps the most biologically compelling data yet from the REGENCY trial, with evidence that obinutuzumab induces deep intrarenal B-cell depletion alongside markedly higher rates of histological remission.

Read Article
#SLE Rx options Determining #MOA #TYK2 #sig w #deucravacitinib #IFN sig in active #SLE ⬇️ in #anifrolumab #upa #deucra #repeat renal #bx in #obinutuzimab ➡️ Clears B cells #Dapriluzimab & other MOAs ⬇️AntiDNA ⬆️complements #EULARbest @RheumNow #EULAR2026 #POS1364, OP0160,336

Janet Pope @Janetbirdope( View Tweet )

5 top abstracts in #Myositis @eular_org 1 #Nailfold #capillaries as an early marker of #IIM Rx 2 #brepocitinib +RCT #DM 3 & rapid skin improvement #CLASI 4 #Ab may help #IBM but neg primary endpoint 5 #criteria for #antisynthetase #EULAR2026 @RheumNow OP0168, 0166, 0164 POS264

Janet Pope @Janetbirdope( View Tweet )

Is there enough data to recommend #rituximab For #ILD in #rheumatoid #arthritis @RheumNow #EULAR2026

Janet Pope @Janetbirdope( View Tweet )

And now does MRI do better than US at predicting RA progression in at risk pts? Short answer: No likely too sensitive! 130 anti-CCP+ symptomatic pts 36.9% progressed BL US positivity predicted progression HR 2.8 MRI showed prevalence of subclinical disease synovitis >80%

Aurelie Najm @AurelieRheumo( View Tweet )

#EULAR2026 POS0172 #Lupus arthritis is the most common domain in RCTs but SLEDAI-MSK or BILAG-MSK isn’t satisfactory. Look out for the role out of LAMDA once externally validated using independent trial datasets. 4 candidates: SJC28, ESR, VAS Phy MSK, & VAS Pa Pain @RheumNow https://t.co/QJ51ETLSSN

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Can AI spot RA inflammation from a thermal hand scan? Cohort 100 RA pts AI model analysing thermal images detected US PD+ wrist inflammation AUC 0.87 Main features wrist temperature & heat-pattern With all due validation could this be the next mass screening tool for RA? https://t.co/2AzXj5yQJI

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
No big surprise here, deucravacitinib does as well without MTX Pooled analysis of 52wk data of POETYK PSA Same ACR20/50/70 and MDA response profiles also similar safety profiles #POS0288 #EULAR2026 @RheumNow https://t.co/XqLfZstRuS

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
A biomarker for CV disease in RA? Anti-CXCR3 antibodies asso w/ atherosclerosis Confirmed in a validation cohort Adding Ab profile to the mSCORE increases AUC from 0.6 to 0.9 Sens from 30 to 69% How does it compare with other ways of detecting atherosclerosis? #POS0899 https://t.co/O7bsLrVyzo

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
What is the @Official_ASAS recommended instrument for evaluating peripheral disease activity in axial and peripheral spondyloarthritis? 👉 DAPSA44 ✔️Good construct validity ✔️ High discriminatory capacity From the ASAS-Sparadise study #EULAR2026 @RheumNow https://t.co/Jbdvpn95jE

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )
#EULAR2026 POS0306 Can we predict #lupus nephritis pts who would achieve CR at 12 mths? Monocentric study used M.Learning: developed & internally validated 5 Clinical Score (LUPRED) with AUC 0.75 training set, 0.78 validation. Simple to use but needs external validation @RheumNow https://t.co/1VRE1yBCac

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Can we finally personalize MTX dosing in #RA? liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay (n=59): MTX-PG3 levels ↑ with dose and age, ↓ with higher disease activity and concomitant biologics. Route (oral vs SC) didn't matter. @RheumNow #EULAR2026 POS0251

Jiha Lee @JihaRheum( View Tweet )

SPARTAN-SSR: New quantitative criteria: BME in ≥3 consecutive slices OR any two of (BME, Erosion, Fat lesion each in ≥3 SIJ quadrants) or ankylosis in ≥3 halves achieves 88-96% sensitivity and 90-98% specificity across 3 cohorts. Precision #axSpA imaging. Abstr OP0100

Antoni Chan MD (Prof) @synovialjoints( View Tweet )

#proof of #concept in #Sjogren’s #dis #lanalumab Treatment reduced in #SjD ✅reduced B cells in #salivary #glands —nearly complete depletion in serum ✅reduced B cell activation ✅improved #inflammation of #parotid & #submandibular glands @RheumNow #EULAR2026 #OP0163 #POS0284

Janet Pope @Janetbirdope( View Tweet )

EULAR flags

Updates in SLE and APS

2026 EULAR Press Release

Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) often overlap. While there have been some therapeutic advances, significant needs remain around diagnosis and monitoring, with a gap around definitions and biomarkers for refractory disease or specific subsets. EULAR – The

Read Article

Therapeutic Updates

ILD Treatment and Guidelines

Hinze title card
Watch our 11-video series on ILD Treatment and Guidelines including videos on assessing ILD, guidelines caveats and concerns, and more.
Read Post

Recent Blogs

Advanced Practice Rheum

Systemic Lupus Erythematosus

Jack Cush, MD
APR SLE VIDEO COVER
Dr. Cush reviews systemic lupus erythematosus.
Read Article

Autoantibodies Anonymous

Artie Kavanaugh, MD
AutoAb.Token
At first, it seemed similar to many other such sessions – a circle of folding chairs, a group of colleagues whose visages exuded understanding and acceptance – but this was special. I started the meeting…. “Hi, my name is Artie.”
Read Post
Advanced Practice Rheum

Rheumatoid & Inflammation Testing

Jack Cush, MD
APR Rheum and Inflammation Testing Cover
Master the dos and don'ts of ordering RF, CCP (ACPA), and inflammatory markers that could transform your diagnostic accuracy.
Read Article
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Podcasts

  • EULAR 2021 - Day2d 00:23:12
×